A retrospective, multicenter study of activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma patients
Latest Information Update: 10 Jul 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 10 Jul 2021 New trial record
- 01 Jul 2021 Results published in the Cancer Immunology Immunotherapy